James Peyer - Jul 10, 2023 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Signature
/s/ James Peyer
Stock symbol
SNSE
Transactions as of
Jul 10, 2023
Transactions value $
$0
Form type
4
Date filed
7/12/2023, 04:29 PM
Previous filing
Aug 1, 2022
Next filing
Aug 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNSE Common Stock Award $0 +4.47K +0.09% $0.00 5.24M Jul 10, 2023 See footnote F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNSE Stock Option (Right to Buy) Award $0 +14.6K $0.00 14.6K Jul 10, 2023 Common Stock 14.6K $1.22 See footnote F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer through such vesting date.
F2 These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.
F3 The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.